Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
| Market Cap | Shares Float | Float Held by Institutions % | Shares Outstanding | Shares Authorized | Institutional Own % |
|---|---|---|---|---|---|
| 35.20 M | 3.67 M | Unavailable | 5.37 M | 150.00 M | 74.50% |
| Date of Short Interest by FINRA | Shares Sold Short | Short Float % | Insider Own % | Number Institutions Holding Shares | MVPHS |
|---|---|---|---|---|---|
| 31-Aug-2023 | 0.06 M | 1.31% | 0.20% | Unavailable | $34.13 M |
| Report Link | Date of Report | Stock Split Info | Stock Split Ratio |
|---|---|---|---|
| Press Release | 11-Aug-2023 | AUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) (the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company’s common stock at a special meeting of the Company held on August 11, 2023. The reverse stock split will take effect after the close of trading on The Nasdaq Capital Market at 5:00 p.m. Eastern Time, on Friday, August 11, 2023. The Company’s common stock will open for trading under a new CUSIP number 608550 208 on The Nasdaq Capital Market on August 14, 2023, on a split-adjusted basis under the current ticker symbol "MTEM." The reverse stock split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. | 1-for-15 |
| Financial Doc Link | Date of Doc | Cash Equivalents | Marketable Securities | Burn Rate Operating Activities (monthly) | Operating Expenses (monthly) | Estimated Months Left of Cash |
|---|---|---|---|---|---|---|
| 10-Q | 10-Aug-2023 | $4.95 M | $28.86 M | $0.01 M | $1.73 M | 643.91 |
| Current Assets | Current Liabilities | Working Capital | Total Assets | Total Liabilities | Total Revenues (12 mo) |
|---|---|---|---|---|---|
| $11.82 M | $26.94 M | -$15.11 M | $35.51 M | $44.19 M | $50.34 M |
Dilutive convertible shares can impact a stock's price by increasing the number of outstanding shares, potentially reducing the value of existing shares and decreasing the stock price.
Stock Warrants can increase share count when exercised. This dilutions affects earnings per share and potentially reduces stock value and impacting investments.
The liquidity and capital resources provides information on the company's cash position, debt levels, and ability to generate cash, indicating its financial stability and potential for growth.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Sign up to see if this company has any shelf registrations pending effect
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements pending effect
Company current reports can impact investments by providing important information on material events and changes at the company, affecting the stock price and potential for gains or losses.